Worldwide Major Depressive Disorder Pipeline Report 2016 - Review of 36 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Major Depressive Disorder Overview
  3. Therapeutics Development
  4. Pipeline Products for Major Depressive Disorder - Overview
  5. Pipeline Products for Major Depressive Disorder - Comparative Analysis
  6. Major Depressive Disorder - Therapeutics under Development by Companies
  7. Major Depressive Disorder - Therapeutics under Investigation by Universities/Institutes
  8. Major Depressive Disorder Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Major Depressive Disorder - Products under Development by Companies
  13. Major Depressive Disorder - Products under Investigation by Universities/Institutes
  14. Major Depressive Disorder - Companies Involved in Therapeutics Development
  • Aequus Pharmaceuticals Inc.
  • Alkermes Plc
  • Allergan Plc
  • Angelini Group
  • Azevan Pharmaceuticals, Inc.
  • BioCrea GmbH
  • Bristol-Myers Squibb Company
  • Cerecor Inc.
  • e-Therapeutics Plc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Hua Medicine Ltd.
  • Intra-Cellular Therapies, Inc.
  • Johnson & Johnson
  • Lead Discovery Center GmbH
  • Les Laboratoires Servier SAS
  • Luye Pharma Group Ltd.
  • Mapreg S.A.S.
  • Methylation Sciences Inc.
  • miCure Therapeutics Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Neuralstem, Inc.
  • nLife Therapeutics, S.L.
  • Otsuka Holdings Co., Ltd.
  • Pherin Pharmaceuticals, Inc.
  • Reviva Pharmaceuticals Inc.
  • Richter Gedeon Nyrt.
  • Saniona AB
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Suven Life Sciences Ltd.
  • Takeda Pharmaceutical Company Limited
  • TRImaran Pharma, Inc.
  • Turing Pharmaceuticals AG

For more information visit http://www.researchandmarkets.com/research/wl3z75/major_depressive

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Mental Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Mental Disorders Drugs